KRAS molecular glues inhibit KRAS activity by binding to cellular chaperone proteins (such as cyclophilin A, CYPA) to form a ternary complex. The formation of this ternary complex not only blocks the RAS/RAF signaling pathway but also blocks the RAS/SOS1 and RAS/PI3K signaling pathways, thus demonstrating superior inhibitory activity compared to small-molecule inhibitors. Our integrated platform employs advanced in vitro assays to explore these KRAS molecular glues, including KRAS/CYPA ternary complex assay, KRAS(ON)/CYPA/cRAF binding assay, 2D/3D cell proliferation assay, ERK phosphorylation detection, and cellular NanoBRET assay for RAS-RAF disruption. It also includes a p-ERK panel and a 2D/3D cell panel. Overall, we provide a comprehensive platform for the screening and evaluation of KRAS molecular glues, offering a scientific basis for the clinical application of KRAS molecular glues.
We present an integrated hit discovery platform for radiopharmaceutical drug conjugates (RDCs) that synergizes high-throughput biophysical screening (SPR, SPS) with phage display technology to rapidly identify and optimize high-affinity cyclic peptide binders against oncology targets. This platform addresses critical challenges in RDC development by providing a streamlined solution for hit discovery, optimization, and validation.
Our methodology employs parallel in vitro biophysical test, phage display library screening. Target validation was achieved through engineered recombinant protein constructs (including PSMA, DLL3 and GPC3) and isogenic cell lines with uniform target expression. Comprehensive evaluation was performed using modular functional assays measuring binding affinity and cellular internalization kinetics.
This platform will significantly accelerate the RDC development pipeline—especially for hit binder identification for neo tumor antigens or other validated surface proteins like GPCRs, transporters—while ensuring optimal tumor targeting and minimized off-target effects.
Early assessment of candidate drug safety is critical in pharmaceutical development to mitigate post-market withdrawals and reduce potential risks. Approximately 75% of Adverse Drug Reactions (ADRs) are dose-dependent (Type A), often mediated by interactions with unintended off-target proteins. Traditional binding assays have limitations in predicting functional biological effects. To address this challenge, this study aims to investigate how an in vitro secondary pharmacology screening strategy, utilizing a functional assay format, can enable more accurate identification of potential safety liabilities early in drug discovery by providing richer pharmacological data.
The characterization of biomolecular interactions is fundamental to drug discovery, particularly for complex modalities such as small molecules, molecular glues (MG), and PROTACs. This study presents a comparative analysis of several key biophysical technologies, with a focus on the innovative DIANTHUS platform.
DIANTHUS combines Spectral Shift-based detection with Time-Resolved Immuno-FRET (TRIC) to deliver superior performance in homogeneous assays. Compared to established techniques like HTRF and SPR, DIANTHUS demonstrates exceptional sensitivity, a broad dynamic range, and remarkable resilience to compound interference. These attributes make it an ideal solution for challenging applications, including the high-throughput screening and precise mechanistic study of molecular glues and PROTACs, which function by inducing or stabilizing protein-protein interactions. Our findings position the DIANTHUS platform as a powerful and versatile tool for accelerating the development of next-generation therapeutic agents.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
